Transplanted human amniotic membrane-derived mesenchymal stem cells ameliorate carbon tetrachloride-induced liver cirrhosis in mouse
DingGuo Zhang, MinYue Jiang, DengShun Miao, DingGuo Zhang, MinYue Jiang, DengShun Miao
Abstract
Background: Human amniotic membrane-derived mesenchymal stem cells (hAMCs) have the potential to reduce heart and lung fibrosis, but whether could reduce liver fibrosis remains largely unknown.
Methodology/principal findings: Hepatic cirrhosis model was established by infusion of CCl₄ (1 ml/kg body weight twice a week for 8 weeks) in immunocompetent C57Bl/6J mice. hAMCs, isolated from term delivered placenta, were infused into the spleen at 4 weeks after mice were challenged with CCl₄. Control mice received only saline infusion. Animals were sacrificed at 4 weeks post-transplantation. Blood analysis was performed to evaluate alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Histological analysis of the livers for fibrosis, hepatic stellate cells activation, hepatocyte apoptosis, proliferation and senescence were performed. The donor cell engraftment was assessed using immunofluorescence and polymerase chain reaction. The areas of hepatic fibrosis were reduced (6.2%±2.1 vs. control 9.6%±1.7, p<0.05) and liver function parameters (ALT 539.6±545.1 U/dl, AST 589.7±342.8 U/dl,vs. control ALT 139.1±138.3 U/dl, p<0.05 and AST 212.3±110.7 U/dl, p<0.01) were markedly ameliorated in the hAMCs group compared to control group. The transplantation of hAMCs into liver-fibrotic mice suppressed activation of hepatic stellate cells, decreased hepatocyte apoptosis and promoted liver regeneration. More interesting, hepatocyte senescence was depressed significantly in hAMCs group compared to control group. Immunofluorescence and polymerase chain reaction revealed that hAMCs engraftment into host livers and expressed the hepatocyte-specific markers, human albumin and α-fetoproteinran.
Conclusions/significance: The transplantation of hAMCs significantly decreased the fibrosis formation and progression of CCl₄-induced cirrhosis, providing a new approach for the treatment of fibrotic liver disease.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol. 2007;47:598–607.
- Kisseleva T, Gigante E, Brenner DA. Recent advances in liver stem cell therapy. Curr Opin Gastroenterol. 2010;26:395–402.
- Huang YW, Hu JT, Yang SS. Hepatology; 2010. Complications of alcoholic liver cirrhosis: Active assessment by endoscopy and sonography.
- Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, et al. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology. 2010;52:349–359.
- Park JK, Ki MR, Lee HR, Hong IH, Ji AR, et al. Vitamin C deficiency attenuates liver fibrosis by way of up-regulated peroxisome proliferator-activated receptor-gamma expression in senescence marker protein 30 knockout mice. Hepatology. 2010;51:1766–1777.
- Muhanna N, Tair LA, Doron S, Amer J, Azzeh M, et al. Gut; 2010. Amelioration of hepatic fibrosis by NK cell activation.
- Neuberger J, Gimson A, Davies M, Akyol M, O'Grady J, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut. 2008;57:252–257.
- Vizzutti F, Arena U, Nobili V, Tarquini R, Trappoliere M, et al. Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol. 2009;8:89–94.
- Zatonski WA, Sulkowska U, Manczuk M, Rehm J, Boffetta P, et al. Liver Cirrhosis Mortality in Europe, with Special Attention to Central and Eastern Europe. Eur Addict Res. 2010;16:193–201.
- Morrison DS, Boyd AA, Richardson T. Liver cirrhosis mortality rates in Britain. Lancet. 2006;367:1899; author reply 1900.
- Chernykh ER, Starostina NM, Paltsev AI, Leplina OY, Shevela EY, et al. Autologous bone marrow cells in the treatment of cirrhosis of the liver. Bull Exp Biol Med. 2007;144:640–645.
- Pai M, Zacharoulis D, Milicevic MN, Helmy S, Jiao LR, et al. Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis. Am J Gastroenterol. 2008;103:1952–1958.
- Mohamadnejad M, Namiri M, Bagheri M, Hashemi SM, Ghanaati H, et al. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J Gastroenterol. 2007;13:3359–3363.
- Salama H, Zekri AR, Zern M, Bahnassy A, Loutfy S, et al. Cell Transplant; 2010. Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases.
- Houlihan DD, Newsome PN. Critical review of clinical trials of bone marrow stem cells in liver disease. Gastroenterology. 2008;135:438–450.
- Khan AA, Shaik MV, Parveen N, Rajendraprasad A, Aleem MA, et al. Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. Cell Transplant. 2010;19:409–418.
- Bailo M, Soncini M, Vertua E, Signoroni PB, Sanzone S, et al. Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation. 2004;78:1439–1448.
- Zhao P, Ise H, Hongo M, Ota M, Konishi I, et al. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Transplantation. 2005;79:528–535.
- Tsuji H, Miyoshi S, Ikegami Y, Hida N, Asada H, et al. Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. Circ Res. 2010;106:1613–1623.
- Marcus AJ, Coyne TM, Rauch J, Woodbury D, Black IB. Isolation, characterization, and differentiation of stem cells derived from the rat amniotic membrane. Differentiation. 2008;76:130–144.
- Cargnoni A, Gibelli L, Tosini A, Signoroni PB, Nassuato C, et al. Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. Cell Transplant. 2009;18:405–422.
- Jeong WI, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology. 2006;44:1441–1451.
- Moriya K, Yoshikawa M, Saito K, Ouji Y, Nishiofuku M, et al. Embryonic stem cells develop into hepatocytes after intrasplenic transplantation in CCl4-treated mice. World J Gastroenterol. 2007;13:866–873.
- Cai J, Ito M, Nagata H, Westerman KA, Lafleur D, et al. Treatment of liver failure in rats with end-stage cirrhosis by transplantation of immortalized hepatocytes. Hepatology. 2002;36:386–394.
- Nieto N, Cederbaum AI. S-adenosylmethionine blocks collagen I production by preventing transforming growth factor-beta induction of the COL1A2 promoter. J Biol Chem. 2005;280:30963–30974.
- Yang YJ, Qian HY, Huang J, Geng YJ, Gao RL, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J. 2008;29:1578–1590.
- Kim H, Park JS, Choi YJ, Kim MO, Huh YH, et al. Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy. Stem Cells. 2009;27:1686–1696.
- Gao F, He T, Wang H, Yu S, Yi D, et al. A promising strategy for the treatment of ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Can J Cardiol. 2007;23:891–898.
- Yokoi Y, Namihisa T, Matsuzaki K, Miyazaki A, Yamaguchi Y. Distribution of Ito cells in experimental hepatic fibrosis. Liver. 1988;8:48–52.
- Roderfeld M, Rath T, Voswinckel R, Dierkes C, Dietrich H, et al. Bone marrow transplantation demonstrates medullar origin of CD34+ fibrocytes and ameliorates hepatic fibrosis in Abcb4-/- mice. Hepatology. 2010;51:267–276.
- Paik YH, Kim JK, Lee JI, Kang SH, Kim DY, et al. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut. 2009;58:1517–1527.
- Carotti S, Morini S, Corradini SG, Burza MA, Molinaro A, et al. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C. Liver Transpl. 2008;14:806–814.
- Salguero Palacios R, Roderfeld M, Hemmann S, Rath T, Atanasova S, et al. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide-induced hepatic fibrosis in mice. Lab Invest. 2008;88:1192–1203.
- Wu J, Danielsson A, Zern MA. Toxicity of hepatotoxins: new insights into mechanisms and therapy. Expert Opin Investig Drugs. 1999;8:585–607.
- Takehara T, Tatsumi T, Suzuki T, Rucker EB, 3rd, Hennighausen L, et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology. 2004;127:1189–1197.
- Watanabe A, Hashmi A, Gomes DA, Town T, Badou A, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology. 2007;46:1509–1518.
- Morita M, Watanabe Y, Akaike T. Protective effect of hepatocyte growth factor on interferon-gamma-induced cytotoxicity in mouse hepatocytes. Hepatology. 1995;21:1585–1593.
- Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med. 1999;5:226–230.
- Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 2002;16:935–942.
- Lefkowitch JH. Hepatobiliary pathology. Curr Opin Gastroenterol. 2008;24:269–277.
- Trak-Smayra V, Contreras J, Dondero F, Durand F, Dubois S, et al. Role of replicative senescence in the progression of fibrosis in hepatitis C virus (HCV) recurrence after liver transplantation. Transplantation. 2004;77:1755–1760.
- Alani RM, Young AZ, Shifflett CB. Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci U S A. 2001;98:7812–7816.
- Roninson IB. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002;179:1–14.
- Autiero I, Costantini S, Colonna G. Human sirt-1: molecular modeling and structure-function relationships of an unordered protein. PLoS One. 2009;4:e7350.
- Aksoy P, Escande C, White TA, Thompson M, Soares S, et al. Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem Biophys Res Commun. 2006;349:353–359.
- Scalera F, Fulge B, Martens-Lobenhoffer J, Heimburg A, Bode-Boger SM. Red wine decreases asymmetric dimethylarginine via SIRT1 induction in human endothelial cells. Biochem Biophys Res Commun. 2009;390:703–709.
- Beckman KB, Ames BN. The free radical theory of aging matures. Physiol Rev. 1998;78:547–581.
- Tamagawa T, Oi S, Ishiwata I, Ishikawa H, Nakamura Y. Differentiation of mesenchymal cells derived from human amniotic membranes into hepatocyte-like cells in vitro. Hum Cell. 2007;20:77–84.
Source: PubMed